BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10951342)

  • 1. Prognostic impact of INK4A deletion in Ewing sarcoma.
    Wei G; Antonescu CR; de Alava E; Leung D; Huvos AG; Meyers PA; Healey JH; Ladanyi M
    Cancer; 2000 Aug; 89(4):793-9. PubMed ID: 10951342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.
    de Alava E; Kawai A; Healey JH; Fligman I; Meyers PA; Huvos AG; Gerald WL; Jhanwar SC; Argani P; Antonescu CR; Pardo-Mindan FJ; Ginsberg J; Womer R; Lawlor ER; Wunder J; Andrulis I; Sorensen PH; Barr FG; Ladanyi M
    J Clin Oncol; 1998 Apr; 16(4):1248-55. PubMed ID: 9552022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA.
    Hayashi M; Chu D; Meyer CF; Llosa NJ; McCarty G; Morris CD; Levin AS; Wolinsky JP; Albert CM; Steppan DA; Park BH; Loeb DM
    Cancer; 2016 Oct; 122(19):3015-23. PubMed ID: 27351911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
    Lerman DM; Monument MJ; McIlvaine E; Liu XQ; Huang D; Monovich L; Beeler N; Gorlick RG; Marina NM; Womer RB; Bridge JA; Krailo MD; Randall RL; Lessnick SL;
    Pediatr Blood Cancer; 2015 May; 62(5):759-65. PubMed ID: 25464386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor.
    Roberto GM; Vieira GM; Delsin LEA; Silva MO; Hakime RG; Engel EE; Scrideli CA; Tone LG; Brassesco MS
    Cancer Genet; 2019 Jan; 230():21-27. PubMed ID: 30470587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of tumor suppressor proteins in the Ewing family of tumors.
    Maitra A; Roberts H; Weinberg AG; Geradts J
    Arch Pathol Lab Med; 2001 Sep; 125(9):1207-12. PubMed ID: 11520274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ATR inhibitors as single agents in Ewing sarcoma.
    Nieto-Soler M; Morgado-Palacin I; Lafarga V; Lecona E; Murga M; Callen E; Azorin D; Alonso J; Lopez-Contreras AJ; Nussenzweig A; Fernandez-Capetillo O
    Oncotarget; 2016 Sep; 7(37):58759-58767. PubMed ID: 27577084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis.
    Honoki K; Stojanovski E; McEvoy M; Fujii H; Tsujiuchi T; Kido A; Takakura Y; Attia J
    Cancer; 2007 Sep; 110(6):1351-60. PubMed ID: 17661343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.
    Tilan JU; Krailo M; Barkauskas DA; Galli S; Mtaweh H; Long J; Wang H; Hawkins K; Lu C; Jeha D; Izycka-Swieszewska E; Lawlor ER; Toretsky JA; Kitlinska JB
    Cancer; 2015 Mar; 121(5):697-707. PubMed ID: 25387699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma.
    Ginsberg JP; de Alava E; Ladanyi M; Wexler LH; Kovar H; Paulussen M; Zoubek A; Dockhorn-Dworniczak B; Juergens H; Wunder JS; Andrulis IL; Malik R; Sorensen PH; Womer RB; Barr FG
    J Clin Oncol; 1999 Jun; 17(6):1809-14. PubMed ID: 10561219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency.
    Chen Y; Hesla AC; Lin Y; Ghaderi M; Liu M; Yang C; Zhang Y; Tsagkozis P; Larsson O; Haglund F
    Mol Oncol; 2020 May; 14(5):1101-1117. PubMed ID: 32115849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
    Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H
    J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.
    Mackintosh C; Ordóñez JL; García-Domínguez DJ; Sevillano V; Llombart-Bosch A; Szuhai K; Scotlandi K; Alberghini M; Sciot R; Sinnaeve F; Hogendoorn PC; Picci P; Knuutila S; Dirksen U; Debiec-Rychter M; Schaefer KL; de Álava E
    Oncogene; 2012 Mar; 31(10):1287-98. PubMed ID: 21822310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival.
    Orlow I; Drobnjak M; Zhang ZF; Lewis J; Woodruff JM; Brennan MF; Cordon-Cardo C
    J Natl Cancer Inst; 1999 Jan; 91(1):73-9. PubMed ID: 9890173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of P53 status in Ewing sarcoma.
    de Alava E; Antonescu CR; Panizo A; Leung D; Meyers PA; Huvos AG; Pardo-Mindán FJ; Healey JH; Ladanyi M
    Cancer; 2000 Aug; 89(4):783-92. PubMed ID: 10951341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma.
    Lynn M; Wang Y; Slater J; Shah N; Conroy J; Ennis S; Morris T; Betts DR; Fletcher JA; O'Sullivan MJ
    Diagn Mol Pathol; 2013 Jun; 22(2):76-84. PubMed ID: 23628818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H
    Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA sequencing and functional studies of patient-derived cells reveal that neurexin-1 and regulators of this pathway are associated with poor outcomes in Ewing sarcoma.
    Roundhill EA; Chicon-Bosch M; Jeys L; Parry M; Rankin KS; Droop A; Burchill SA
    Cell Oncol (Dordr); 2021 Oct; 44(5):1065-1085. PubMed ID: 34403115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.